Theravance Biopharma (TBPH) Retained Earnings (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Retained Earnings of -$62000.0 for Q1 2026, down 100.01% year-over-year from $1.1 billion in Q1 2025, and down 100.01% quarter-over-quarter from $1.2 billion in Q4 2025.
Theravance Biopharma (TBPH) Retained Earnings (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Retained Earnings for 13 consecutive years, with -$62000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 100.01% year-over-year to -$62000.0; the TTM figure through Mar 2026 stood at -$62000.0 (down 100.01% YoY), while the FY2025 annual figure was $1.2 billion, up 219.76% from the prior year.
- Retained Earnings retreated to -$62000.0 in Q1 2026 per TBPH's latest filing, from $1.2 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $1.3 billion in Q4 2022 and bottomed at -$1.8 billion in Q2 2022.
- Historically, Retained Earnings has averaged $64.7 million across 5 years, with a median of -$22000.0 in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings sank 22002350.0% — and 2023, when it soared 235.97%.
- Theravance Biopharma's Retained Earnings stood at $1.3 billion in 2022, then sank by 170.16% to -$909.1 million in 2023, then fell by 6.21% to -$965.5 million in 2024, then surged by 219.76% to $1.2 billion in 2025, then slumped by 100.01% to -$62000.0 in 2026.
- Business Quant data shows TBPH's Retained Earnings at -$62000.0 in Q1 2026, $1.2 billion in Q4 2025, and -$920.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 1.16 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Bn |
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | 1.16 Bn |
| Sep 30, 2025 | -920.65 Mn |
| Jun 30, 2025 | -10,000.00 |
| Mar 31, 2025 | 1.15 Bn |
| Dec 31, 2024 | -965.52 Mn |
| Sep 30, 2024 | 1.14 Bn |
| Jun 30, 2024 | -22,000.00 |
| Mar 31, 2024 | 1.13 Bn |
| Dec 31, 2023 | -909.10 Mn |
| Sep 30, 2023 | 1.15 Bn |
| Jun 30, 2023 | -286,000.00 |
| Mar 31, 2023 | 1.25 Bn |
| Dec 31, 2022 | 1.30 Bn |
| Sep 30, 2022 | -843.55 Mn |
| Jun 30, 2022 | -1.76 Bn |
| Mar 31, 2022 | -1.75 Bn |
| Dec 31, 2021 | -1.73 Bn |
| Sep 30, 2021 | 14,000.00 |